Rilpivirine

Drug Profile

Rilpivirine

Alternative Names: Edurant; G002 - Janssen Therapeutics; G007; G009-01; JNJ-16150108; Long-acting TMC278; R 278474; Rilpivirine hydrochloride; TMC 278; TMC278 LA (IM injection) - Tibotec; TMC278LA

Latest Information Update: 30 May 2017

Price : $50

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Janssen R&D Ireland; Janssen Therapeutics; PATH
  • Class Antiretrovirals; Nitriles; Pyrimidines; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 27 Apr 2017 Janssen Research & Development plans a phase I trial in Healthy volunteers in USA (IM, Controlled release) (NCT03127189)
  • 20 Apr 2017 Janssen Research & Development initiates a phase I pharmacokinetics trial in Healthy volunteers in USA (IM, Controlled release) (NCT03127189)
  • 01 Apr 2016 Janssen completes a phase I trial in volunteers in Belgium (NCT2547870)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top